IP Library Granted Patent US 8,642,261
Granted Patent B2
US 8,642,261 · App. 13/126,081 · Granted Feb 4, 2014

Genetic marker for detection of human papillomavirus

Inventors: Hovsep S. Melkonyan (Princeton, NJ); Samuil R. Umansky (Princeton, NJ); Zhenghan Xin (Newtown, PA)
Assignee: Trovagene, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,261
App. No.
13/126,081
Granted
Feb 4, 2014
Kind
B2
Abstract

The invention provides compositions and methods for the differential detection of high risk forms of HPV from a urine sample provided by a patient. Specifically, the invention provides primers and probes that specifically recognize and bind sequences within the E 1 gene of HPV. Detection of high risk forms of HPV identify individuals at risk of developing or in the early stages of cervical carcinoma.

Claims (29)

1. An oligonucleotide having the sequence 5′-CAGGCAGAATTAGAGRCAGC (SEQ ID NO:41 or 99), wherein R is A or G, and the oligonucleotide is optionally labeled.

2. The oligonucleotide according to claim 1 , wherein the oligonucleotide is fluorescently labeled.

3. The oligonucleotide according to claim 2 , wherein the oligonucleotide is XEN-HPV-FAM-F (SEQ ID NO:98).

4. A pair of oligonucleotide primers comprising a forward primer that is the oligonucleotide of claim 1 and a reverse primer having the sequence 5′-TCCACCACAWACTTTCGTTTTA (SEQ ID NO:42 or 100), wherein W is T or A.

5. The oligonucleotide primers according to claim 4 , wherein the forward primer is fluorescently labeled.

6. The oligonucleotide primers according to claim 5 , wherein the forward primer is XEN-HPV-FAM-F (SEQ ID NO:98) and the reverse primer is XEN-HPV-R (SEQ ID NO:100).

7. A kit comprising the oligonucleotide according to claim 1 .

8. A kit comprising the oligonucleotide according to claim 2 .

9. A kit comprising the oligonucleotide according to claim 3 .

10. A kit comprising the oligonucleotide primers according to 4 .

11. A kit comprising the oligonucleotide primers according to 5 .

12. A kit comprising the oligonucleotide primers according to 6 .

13. An oligonucleotide primer having the sequence 5′-TCCACCACAWACTTTCGTTTTA (SEQ ID NO:42 or 100), wherein W is T or A.

14. A method of detecting human papillomavirus (HPV) infection in a patient, the method comprising:

detecting one or more sequences of the E1 gene of HPV in a urine sample obtained from a patient,

wherein said detecting comprises hybridization of said one or more sequences to the oligonucleotide of claim 1 and wherein detection of one or more sequences of the E1 gene of HPV indicates the presence of at least one HPV infection in a patient.

15. The method of claim 14 , wherein said amplifying comprises a technique selected from the polymerase chain reaction (PCR); nested primer PCR; Real Time PCR; NA hybridization; Cyclic Probe Reaction; Single-Strand Conformation Polymorphism (SSCP); Strand Displacement Amplification (STA); and Restriction Fragment Length Polymorphism (RFLP).

16. The method of claim 14 , wherein said detecting comprises

(a) amplifying nucleic acids, from said urine sample obtained from a patient, with said oligonucleotide as a forward primer to produce amplified E1 gene sequences; and

(b) detecting the amplified E1 gene sequences.

17. The method of claim 16 , wherein said amplifying further comprises an oligonucleotide having the sequence 5′-TCCACCACAWACTTTCGTTTTA (SEQ ID NO:42 or 100), wherein W is T or A.

18. The method of claim 17 , wherein said amplifying comprises XEN-HPV-FAM-F (SEQ ID NO:98) and XEN-HPV-R (SEQ ID NO:100) as primers.

19. The method of claim 14 , wherein said nucleic acids comprise transrenal DNA.

20. The method of claim 14 , further comprising reducing nucleic acid degradation in the urine sample.

21. The method of claim 20 , wherein reducing nucleic acid degradation comprises inhibiting nuclease activity by increased pH, increased salt concentration, heat inactivation, or by treating said urine sample with a compound selected from the group consisting of: ethylenediaminetetraacetic acid, guanidine-HCl guanidine isothiocyanate, N-lauroylsarcosine, and sodium dodecylsulphate.

22. The method of claim 14 , further comprising substantially isolating said nucleic acids from the urine sample before said amplifying.

23. The method of claim 22 , wherein said isolating is by precipitation or using a solid adsorbent material.

24. The method of claim 14 , further comprising the step of quantifying said amplified E1 gene sequences.

25. The method of claim 14 , wherein said detecting further comprises the extension of said oligonucleotide after hybridization.

Assignments (2)
CHANGE OF NAME Recorded Jun 22, 2020
From: TROVAGENE, INC.
To: CARDIFF ONCOLOGY, INC.
Reel/Frame 053006/0379 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2011
From: MELKONYAN, HOVSEP S.; UMANSKY, SAMUIL R.; XIN, ZHENGHAN
To: TROVAGENE, INC.
Reel/Frame 027207/0769 →
Continuity (2)
Provisional Application 61197850 · Oct 31, 2008
Related Publication 20110318727A1 · Dec 29, 2011